Oncology launch accelerates as core endocrine business finds new life
- Corcept's historical profit engine is Korlym for Cushing's syndrome.
- Lifyorli generated $91.4 million in Q3 2026 for ovarian cancer, up 92 percent from its first quarter.
- Management expects full-year 2026 revenue between $1.1 billion and $1.2 billion.
- The relacorilant Cushing's application faces a December 17, 2026 FDA target date.
- The American Diabetes Association recently recommended cortisol screening for difficult-to-treat diabetes.
Diversification is finally real
Corcept used to be almost entirely dependent on Korlym. That made the company simple to understand but fragile. In March 2026, the FDA approved Lifyorli for platinum-resistant ovarian cancer, and Corcept began selling it in April. That turns Corcept from a Cushing's syndrome company into a commercial business with two distinct growing franchises.
The Lifyorli launch continues to exceed expectations. In the third quarter of 2026, the drug generated $91.4 million in revenue, a 92 percent sequential jump. More than 2,300 patients have started treatment, and prescriptions show early signs of expanding into earlier lines of therapy. This rapid adoption validates the company's expansion into oncology.
The bull case is that Lifyorli continues to ramp quickly, while the legacy endocrine business benefits from new medical guidelines. In October 2026, the American Diabetes Association recommended hypercortisolism screening for difficult-to-treat diabetes. This significantly expands the potential patient pool for Korlym and, if approved on its December 17, 2026 target date, relacorilant.
The bear case remains serious. Korlym faces certain generic pressure after Corcept exhausted its Teva patent appeals in July 2026. Selling and administrative spending jumped to support the new launches. If Lifyorli sales momentum stalls in earlier lines of therapy or the FDA rejects relacorilant again, the company could struggle to offset the eventual decline of its core business.
Specialty drugs fund the pipeline
Corcept makes money by selling specialty medicines in the United States. Korlym and its authorized generic treat high blood sugar in adults with endogenous Cushing's syndrome. Lifyorli, which uses the same active drug as relacorilant, is sold with nab-paclitaxel for certain ovarian cancer patients.
The company relies on cash flow from the established Korlym franchise and the new Lifyorli launch to fund an R&D pipeline of selective cortisol modulators. In the third quarter of 2026, Korlym generated a record $249.1 million while Lifyorli added $91.4 million. Driven by this dual strength, management expects full-year 2026 revenue between $1.1 billion and $1.2 billion.
The model works best when specialty pharmacies, insurers, and doctors move patients through the system quickly. Corcept recently resolved prior authorization and pharmacy transition backlogs, clearing the way to capture strong underlying demand in the endocrine business.
Costs are rising with the bigger ambition. Selling, general, and administrative expenses increased significantly in 2026 to support commercialization. That spending is sensible if both launches work, but painful if either one misses.
Korlym pays, Lifyorli grows
Korlym
Korlym treats hyperglycemia in adult patients with endogenous Cushing's syndrome. It remains the main revenue base, but it faces generic pressure.
Authorized generic Korlym
Corcept launched an authorized generic in June 2024. It helps defend volume, but it also lowers average selling price.
Lifyorli
Lifyorli was approved in March 2026 for certain platinum-resistant ovarian cancer patients. It generated $91.4 million in the third quarter of 2026.
Relacorilant for Cushing's syndrome
Corcept resubmitted the application in June 2026 after a previous rejection. The FDA set a target action date of December 17, 2026.
Miricorilant for MASH
Miricorilant is moving into a Phase 2 trial for daily dosing after showing a 19.2 percent improvement in liver fibrosis in a previous study.
Dazucorilant for ALS
Dazucorilant is planned for a pivotal Phase 3 trial in ALS in 2026. This is a high-risk neurology program.
Nenocorilant in oncology
Nenocorilant is being tested with nivolumab in the Phase 1b SYNERGY trial for solid tumors. It is part of Corcept's broader bet on cortisol modulation in cancer.
One reported segment, two markets
Corcept operates as a single business segment. In Q3 2026, the company generated $249.1 million from endocrinology products and $91.4 million from the newly launched oncology product, Lifyorli.
What can break the story
Korlym generic erosion
High impact · High oddsCorcept lost its final Teva patent appeal in July 2026 when the court denied a rehearing. That finalizes the loss of patent protection and solidifies the long-term threat of revenue and margin erosion from generic entrants.
Lifyorli ramp stalls
High impact · Medium oddsLifyorli started strong with over 2,300 patients by Q3 2026. The next test is moving into earlier lines of therapy. If late-line patients exhaust and earlier adoption proves commercially difficult, Lifyorli may not offset Korlym pressure.
Cushing's regulatory setback
High impact · Medium oddsThe FDA is reviewing the relacorilant resubmission for Cushing's syndrome with a December 17, 2026 target date. A second rejection would permanently impair the endocrine pipeline.
Launch spending outruns revenue
Medium impact · Medium oddsOperating expenses are rising to support the Lifyorli and hypercortisolism launches. If sales do not ramp fast enough to cover these costs, profits and cash flow could stay under pressure.
Legal overhang
Medium impact · Medium oddsCorcept faces an antitrust lawsuit from Teva scheduled for a March 2027 trial. The company is also dealing with a securities class action. These cases can cost money, take management time, and hurt investor trust.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Corcept Therapeutics Incorporated in Finn's Biotechnology industry ranking.

